GMED investors have the opportunity to participate in Globus Medical, Inc. securities fraud investigation with the Schall law firm

Schall Law Firm, a national law firm focused on shareholder rights litigation, announces that it is investigating claims alleging violations of the securities laws on behalf of investors of Globus Medical, Inc. (“Globus” or “the Company”) (NYSE: GMED).

The investigation focuses on whether the company made false and/or misleading statements and/or failed to disclose information relevant to investors. Globus disclosed in an SEC filing dated August 13, 2024 that “on July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA’) following an inspection of our facilities in Audubon, Pennsylvania. In the warning letter, the FDA cited deficiencies in the response letters the company submitted to the FDA following the Form 483, List of Investigational Observations, provided to the company in connection with the inspection that took place from February 15, 2024 to March 7, 2024. The letter describes observed non-conformities in the establishment and maintenance of product complaint procedures, including complaint investigations, trending, risk reconciliation, and Medical Device Report (MDR) procedures, including timely reporting, with respect to the ExcelsiusGPS robotic system.”